Robert Beauchamp
Principal Investigator
Last active: 3/27/2020

  1. Presidential address: evolution. Beauchamp RD (2000) Surgery 128(2): 123-32
    › Primary publication · 10922981 (PubMed)
  2. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Zhang Z, Sheng H, Shao J, Beauchamp RD, DuBois RN (2000) Neoplasia 2(6): 523-30
    › Primary publication · 11228545 (PubMed) · PMC1508084 (PubMed Central)
  3. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. Shao J, Sheng H, DuBois RN, Beauchamp RD (2000) J Biol Chem 275(30): 22916-24
    › Primary publication · 10781597 (PubMed)
  4. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Jo H, Zhang R, Zhang H, McKinsey TA, Shao J, Beauchamp RD, Ballard DW, Liang P (2000) Oncogene 19(7): 841-9
    › Primary publication · 10702792 (PubMed)
  5. Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16(INK4A) fusion peptide in pancreatic cancer cells. Fujimoto K, Hosotani R, Miyamoto Y, Doi R, Koshiba T, Otaka A, Fujii N, Beauchamp RD, Imamura M (2000) Cancer Lett 159(2): 151-8
    › Primary publication · 10996726 (PubMed)
  6. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB (2000) J Clin Oncol 18(19): 3384-9
    › Primary publication · 11013279 (PubMed)
  7. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Sheng H, Shao J, O'Mahony CA, Lamps L, Albo D, Isakson PC, Berger DH, DuBois RN, Beauchamp RD (1999) Oncogene 18(4): 855-67
    › Primary publication · 10023661 (PubMed)
  8. Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells. Saha D, Datta PK, Sheng H, Morrow JD, Wada M, Moses HL, Beauchamp RD (1999) Neoplasia 1(6): 508-17
    › Primary publication · 10935498 (PubMed) · PMC1508120 (PubMed Central)
  9. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD (1999) J Nucl Med 40(11): 1784-91
    › Primary publication · 10565771 (PubMed)
  10. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD (1999) Ann Surg Oncol 6(7): 651-7
    › Primary publication · 10560850 (PubMed)